Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock

The market for GLP-1 agonist weight-loss drugs is giving drug manufacturers a chance to show how hard they're willing to compete based on price when conditions encourage them to do that.

Novo Nordisk, the maker of Wegovy, the top seller in the GLP-1 drug arena, is trying to chase away the pharmacies that make alternative, "compounded" versions of the drug by offering the real thing for $499 per month for patients who pay cash.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Allison Bell

Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.

Core and Group Health
Health Care Reform
Voluntary Benefits
Cost-Containment
Employee-Paid
Employer-Paid